These findings and subsequent evidence suggest that GLP-1 inhibits gastric emptying, food intake, and glucagon secretion supporting to development GLP-1 receptor agonists (GLP-1 RA) for the treatment of type 2 diabetes mellitus (T2DM).325 GLP-1 RAs mainly include exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, benaglutide, and semaglutide. This evidence concerns the gene GCG and type 2 diabetes mellitus.